Bypassing cisplatin resistance in Nrf2 hyperactivated head and neck cancer through effective PI3Kinase targeting.
Yadollahi P, McCord KA, Li Y, Dayoub H, Saab K, Essien F, Hyslop S, Kan E, Ahmed KM, Kirby PR, Putluri V, Ambati CSR, Kami Reddy KR, Castro P, Skinner HD, Coarfa C, Decker WK, Osman AA, Patel R, Myers JN, Lai SY, Putluri N, Johnson FM, Frederick MJ, Hudson WH, Sandulache VC.
Yadollahi P, et al. Among authors: patel r.
bioRxiv [Preprint]. 2025 Jan 16:2025.01.10.632413. doi: 10.1101/2025.01.10.632413.
bioRxiv. 2025.
PMID: 39868226
Free PMC article.
Preprint.